Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.
Pre-injection of mice with vaccinia virus inhibited the subsequent antibody response to a recombinant polypeptide expressed by vaccinia virus. The inhibition was overcome following additional challenges with recombinant vaccinia virus. This suggests that a potential disadvantage in vaccinia-immune individuals can be circumvented and may be outweighed by the advantages of the vector.
Etlinger
H M
HM
Central Research Units, F. Hoffman-La Roche Ltd., Basel, Switzerland.
Altenburger
W
W
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000914:Antibodies, Viral / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D007114:Immunization; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D010963:Plasmodium falciparum / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*
D000913:Antibodies, Protozoan; D000914:Antibodies, Viral; D000953:Antigens, Protozoan; D000939:Epitopes; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic